# Discovering existing medicines that abrogate cellular responses to SARS CoV-2 infection

> **NIH NIH U54** · BROAD INSTITUTE, INC. · 2020 · $1,652,790

## Abstract

PROJECT SUMMARY
Our overall strategy is to screen existing drugs for their unexpected ability to abrogate key aspects of SARS-
CoV-2 infection. The proposal will leverage the infrastructure we have created as part of the LINCS Consortium
to use gene expression profiling to discover existing drugs that either block the cellular mechanisms required for
viral infection, or block the cellular response to infection that causes disease. While there is much biological
learning to be done, the focus of this proposal is not basic biology, but rather on the discovery of drugs that could
be rapidly tested in patients. For this reason, we emphasize existing drugs (those that are either FDA-approved,
EMA-approved, or are in clinical development) because of the pace at which they can be advanced to clinical
trials. Our proposed approach leverages capabilities developed under our Common Fund-supported LINCS
Center for Transcriptomics. First, we have created a “shovel-ready” production-scale data generation capability
that can now be brought to bear on COVID-19. Second, we have assembled a drug repurposing library with
~10,000 drugs that are either FDA-approved or are in clinical development. Third, through our LINCS experience,
we have learned that real power comes from unleashing the world’s scientific community by creating public
resources that can be utilized by others. In this project, we will screen ~10,000 drugs in lung epithelial cells and
monocytic immune cells, using gene expression profiling as the readout. We will make this Drug Repurposing
LINCS dataset immediately publicly available, so that anyone in the research community can query it with
relevant signatures -- including those that have yet to be discovered. High priority drugs identified through
analysis of these data will be subjected to orthogonal tests of antiviral and immune function. An important aspect
of this proposal will be the creation of a COVID-19 Drug Repurposing Portal which will house all of the raw and
processed data generated by this proposal, together with biologist-friendly analytical and visualization tools that
will enable the entire COVID-19 research community to identify top priority drugs for pre-clinical and eventually
clinical testing as anti-COVID-19 therapies.

## Key facts

- **NIH application ID:** 10199270
- **Project number:** 3U54HL127366-06S2
- **Recipient organization:** BROAD INSTITUTE, INC.
- **Principal Investigator:** TODD R. GOLUB
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,652,790
- **Award type:** 3
- **Project period:** 2020-08-21 → 2022-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10199270

## Citation

> US National Institutes of Health, RePORTER application 10199270, Discovering existing medicines that abrogate cellular responses to SARS CoV-2 infection (3U54HL127366-06S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10199270. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*